The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive Symptoms in 80 Patients With Unipolar or Bipolar Depression: a Phase II Exploratory add-on Double Blind Placebo Controlled 2 Week Trial
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs JNJ 39393406 (Primary)
- Indications Bipolar depression; Depressive disorders
- Focus Therapeutic Use
- Acronyms JNJ-DEP
- 24 Jan 2018 Status changed from recruiting to completed.
- 28 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.
- 28 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 May 2017.